Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

AHCO vs INMD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AHCO Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 6–4 Matrix Metrics)

AHCO Overall Winner 6-Pillar Tally: AHCO 3 – 3 INMD Matrix Metrics: AHCO 6 – 4 INMD

As of Nov 20, 2026, AdaptHealth Corp. (AHCO) is the stronger overall head-to-head candidate over InMode Ltd. (INMD) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). AHCO carries a Unified Composite Score of 45.2/100 (HOLD) at $7.20 (7.8x Forward P/E, 3.8% operating margin), whereas INMD carries 37.6/100 (SELL) at $12.42 (9.2x Forward P/E, 17.9% operating margin).

  • Technical & Structure Timing Caution: AHCO trades in a Markup technical trend (SURGE options phase, RSI 57.1); meanwhile INMD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AHCO vs INMD
AHCO NASDAQ Head-to-Head Winner
AdaptHealth Corp. Common Stock
Services-Home Health Care Services
$7.20
-0.69% 1D
Market Cap $989.8M
TTM Revenue $3.44B
Forward P/E 7.8x
Beta / 30D Vol 0.17β · 67% Vol
Unified Composite Score
45.2 / 100 HOLD
Tech 29.0 Fund 46.0 Flow 54.0 Mom 60.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (7.8% over 20 days), RSI 57
RSI-14: 57.1 · SMA20: $6.96 · SMA50: $6.32
INMD NASDAQ
InMode Ltd. Ordinary Shares
Electromedical & Electrotherapeutic Apparatus
$12.42
-2.2% 1D
Market Cap $730.8M
TTM Revenue $374M
Forward P/E 9.2x
Beta / 30D Vol 0.61β · 35% Vol
Unified Composite Score
37.6 / 100 SELL
Tech 25.0 Fund 45.0 Flow 57.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.4%), weak momentum, RSI 31
RSI-14: 31.1 · SMA20: $13.36 · SMA50: $13.89

6-Pillar Scorecard Institutional Category Breakdown (AHCO 3 – 3 INMD)

Columns: Metric · AHCO · INMD
1. Valuation Multiples AHCO
Forward P/E 7.8x 9.2x
Trailing P/E 7.8x 10.8x
PEG Ratio N/M 0.83x
EV / Revenue 0.9x 0.9x
2. Growth & Scale AHCO
Revenue Growth (YoY) +10.9% -1.1%
Earnings Growth (YoY) +6.7% -5.9%
TTM Revenue (USD) $3.44B $374M
Market Cap $989.8M $730.8M
3. Profitability & Quality INMD
Gross Margin 18.2% 76.6%
Operating Margin 3.8% 17.9%
Net Profit Margin -11.8% 20.0%
Return on Equity (ROE) -28.4% 11.4%
4. Balance Sheet & Cash Flow INMD
Cash Generation (TTM) $82M $69M
Cash Flow Margin 2.4% 18.6%
Net Cash / Leverage $1.97B Net Debt (1.67x D/E) $394M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AHCO
Options Structure Phase SURGE CONSOLIDATION
Current IV / %ile 66.9% (12th %ile) 44.2% (12th %ile)
Put/Call OI Skew N/A 0.90x (Balanced)
OBV Trend / Tech Phase NEUTRAL · Markup DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat INMD
OpEx & R&D Intensity 14.4% of Rev ($495M) 58.7% of Rev ($219M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AHCO (6) vs INMD (4)
Institutional Metric AHCO INMD Criterion Row Edge
Market Capitalization
Scale
$989.8M $730.8M Larger Scale AHCO
Trailing P/E Ratio
Valuation
7.8x 10.8x Lower Multiple AHCO
Forward P/E Ratio
Valuation
7.8x 9.2x Lower Multiple AHCO
Revenue Growth (YoY)
Growth
+10.9% -1.1% Higher Growth AHCO
Operating Margin (TTM)
Profitability
3.8% 17.9% Higher Margin INMD
Net Profit Margin
Profitability
-11.8% 20.0% Higher Margin INMD
Return on Equity (ROE)
Capital Efficiency
-28.4% 11.4% Higher ROE INMD
52-Week Range Position
Momentum
24% ($5–$13) 0% ($12–$17) Stronger Trend AHCO
Beta / 30D Volatility
Risk Regime
0.17β · 67% Vol 0.61β · 35% Vol Lower Realized Risk INMD
Unified Institutional Score
Composite Signal
45.2 / 100 (HOLD) 37.6 / 100 (SELL) Higher Composite AHCO
Trailing 12M Revenue (USD)
Operating Scale
$3.44B $374M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
18.2% 76.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.9x EV/Rev 0.83x PEG · 0.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$82M ($1.97B Net Debt (1.67x D/E)) $69M ($394M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AHCO +28.29 pp
AHCO: +16.69% · INMD: -11.6%
3M Horizon AHCO +45.64 pp
AHCO: +27.89% · INMD: -17.75%
6M Horizon INMD +21.49 pp
AHCO: -31.1% · INMD: -9.61%
1Y Horizon INMD +9.28 pp
AHCO: -20.88% · INMD: -11.6%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period AHCO Revenue INMD Revenue AHCO Op. Margin INMD Op. Margin Margin Leader
FY2018 $350M $100M 9.0% 23.5% INMD
FY2019 $530M $160M 5.5% 38.1% INMD
FY2020 $1.06B $210M 6.8% 35.3% INMD
FY2021 $2.45B $360M 9.2% 46.8% INMD
FY2022 $2.97B $450M 6.4% 43.6% INMD
FY2023 $3.20B $490M -18.7% 39.8% INMD
FY2024 $3.26B $390M 8.1% 28.5% INMD
FY2025 $3.24B $370M 2.8% 23.0% INMD

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AHCO SURGE
6d in phase · OBV NEUTRAL
Current IV 66.9%
IV Percentile 12th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact AHCO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
INMD CONSOLIDATION
90d in phase · OBV DISTRIBUTION
Current IV 44.2%
IV Percentile 12th %ile
Put/Call OI Skew 0.90x (Balanced)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact INMD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AHCO Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $989.8M market capitalization and 3.8% operating margin.
OpEx & R&D Reinvestment 14.4% of Rev ($495M)
90D Engineering Disclosures 0 Published
INMD Moat Profile Scale & Operating Efficiency Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $730.8M market capitalization and 17.9% operating margin.
OpEx & R&D Reinvestment 58.7% of Rev ($219M)
90D Engineering Disclosures 0 Published

Investor FAQ AHCO vs INMD Key Questions & Quantitative Answers

As of Nov 20, 2026, AdaptHealth Corp. (AHCO) is the stronger overall head-to-head candidate over InMode Ltd. (INMD) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). AHCO carries a Unified Composite Score of 45.2/100 (HOLD) at $7.20 (7.8x Forward P/E, 3.8% operating margin), whereas INMD carries 37.6/100 (SELL) at $12.42 (9.2x Forward P/E, 17.9% operating margin). Technical & Structure Timing Caution: AHCO trades in a Markup technical trend (SURGE options phase, RSI 57.1); meanwhile INMD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AHCO leads the Growth & Scale pillar: AHCO posts +10.9% YoY revenue growth and +6.7% YoY earnings growth on $3.44B TTM revenue (18.2% gross margin, 3.8% operating margin), compared with INMD at -1.1% YoY revenue growth and -5.9% YoY earnings growth on $374M TTM revenue (76.6% gross margin, 17.9% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), AHCO cumulative revenue shifted +825.7% while INMD shifted +270.0%. In operating R&D and SG&A reinvestment, AHCO deploys 14.4% of Rev ($495M) (0 90-day corporate R&D disclosures) versus 58.7% of Rev ($219M) (0 disclosures) for INMD.

AHCO screens cheaper on headline valuation multiples. AHCO trades at 7.8x Forward P/E, 7.8x Trailing P/E, N/M PEG, and 0.9x EV/Revenue (2.4% FCF margin), whereas INMD trades at 9.2x Forward P/E, 10.8x Trailing P/E, 0.83x PEG, and 0.9x EV/Revenue (18.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AHCO (-28.4% ROE) versus INMD (11.4% ROE) capital efficiency.

In options market volatility and institutional positioning, AHCO carries 66.9% implied volatility (12th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (0.17β · 67% Vol realized risk). By comparison, INMD carries 44.2% implied volatility (12th %ile, Compressed (<25th %ile)), a 0.90x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.61β · 35% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.